目的 探討舒血寧注射液聯(lián)合阿托伐他汀治療慢性硬膜下血腫的臨床療效。方法 選取2016年1月-2017年1月在天津醫(yī)科大學總醫(yī)院濱海醫(yī)院治療的慢性硬膜下血腫患者76例，依據(jù)治療方案的差別分為對照組（38例）和治療組（38例）。對照組口服阿托伐他汀鈣片，20 mg/次，1次/d。治療組在對照組的基礎上靜脈滴注舒血寧注射液，20 mL加入5%葡萄糖溶液250 mL，1次/d。兩組患者均治療30 d。評價兩組患者臨床療效，同時比較治療前后兩組患者CSS和ADL評分以及血腫量和血清學指標。結(jié)果 治療后，對照組和治療組的總有效率分別為81.58%、97.37%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組CSS評分與血腫量均顯著降低，ADL評分升高，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組CSS和ADL評分及血腫量均顯著優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組血清神經(jīng)元特異性烯醇化酶（NSE）、基質(zhì)金屬蛋白酶-9（MMP-9）、腦源性神經(jīng)營養(yǎng)因子（BDNF）水平顯著降低，同組比較差異具有統(tǒng)計學意義（P<0.05）；且治療組上述血清學指標明顯低于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 舒血寧注射液聯(lián)合阿托伐他汀治療慢性硬膜下血腫臨床療效顯著，可有效改善神經(jīng)功能和促進血腫吸收，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Shuxuening Injection combined with atorvastatin in treatment of elderly patients with chronic subdural hematoma. Methods Patients (76 cases) with chronic subdural hematoma in Binhai Hospital of General Hospital Affiliated to Tianjin Medical University from January 2016 to January 2017 were divided into control (38 cases) and treatment (38 cases) groups based on different treatments. Patients in the control group were po administered with Atorvastatin Calcium Tablets, 20 mg/time, once daily. Patients in the treatment group were iv administered with Shuxuening Injection on the basis of the control group, 20 mL added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 30 d. After treatment, clinical efficacy was evaluated, and the CSS and ADL scores, hematoma volume and serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.58% and 97.37%, respectively, and there were differences between two groups (P<0.05). After treatment, the CSS scores and hematoma volume in two groups were significantly decreased, but ADL scores were significantly increased, and the difference was statistically significant in the same group (P<0.05). The CSS score, ADL score, and hematoma volume in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum NSE, MMP-9, and BDNF levels in two groups were significantly decreased, and there were differences in the same group (P<0.05). And these serological indicators in the treatment group were obviously lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shuxuening Injection combined with atorvastatin has clinical significant effect in treatment of elderly patients with chronic subdural hematoma, can effectively improve the nerve function and promote the absorption of hematoma, which has a certain clinical application value.

天津市應用基礎與前沿技術研究計劃重點項目（15JCZDJC36500）